- Home
- SACH vs MRSN Comparison
SACH vs MRSN Comparison
Compare SACH & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- MRSN
- Stock Information
- Founded
- SACH 2010
- MRSN 2001
- Country
- SACH United States
- MRSN United States
- Employees
- SACH N/A
- MRSN N/A
- Industry
- SACH Real Estate Investment Trusts
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- MRSN Health Care
- Exchange
- SACH Nasdaq
- MRSN Nasdaq
- Market Cap
- SACH 46.7M
- MRSN 40.7M
- IPO Year
- SACH 2017
- MRSN 2017
- Fundamental
- Price
- SACH $1.09
- MRSN $0.36
- Analyst Decision
- SACH Hold
- MRSN Strong Buy
- Analyst Count
- SACH 3
- MRSN 5
- Target Price
- SACH $2.25
- MRSN $5.75
- AVG Volume (30 Days)
- SACH 216.2K
- MRSN 2.3M
- Earning Date
- SACH 08-13-2025
- MRSN 08-12-2025
- Dividend Yield
- SACH 18.61%
- MRSN N/A
- EPS Growth
- SACH N/A
- MRSN N/A
- EPS
- SACH N/A
- MRSN N/A
- Revenue
- SACH N/A
- MRSN $34,006,000.00
- Revenue This Year
- SACH N/A
- MRSN N/A
- Revenue Next Year
- SACH $4.52
- MRSN $1.30
- P/E Ratio
- SACH N/A
- MRSN N/A
- Revenue Growth
- SACH N/A
- MRSN N/A
- 52 Week Low
- SACH $0.80
- MRSN $0.26
- 52 Week High
- SACH $3.07
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- SACH 52.20
- MRSN 46.82
- Support Level
- SACH $1.03
- MRSN $0.35
- Resistance Level
- SACH $1.11
- MRSN $0.39
- Average True Range (ATR)
- SACH 0.06
- MRSN 0.03
- MACD
- SACH -0.00
- MRSN -0.00
- Stochastic Oscillator
- SACH 44.07
- MRSN 12.30
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.